Order Article Reprints

Tanriover MD, Aydin OA, Guner R, Yildiz O, Celik I, Doganay HL, Kose S, Akhan S, Akalin EH, Sezer Z, et al. Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines. 2022; 10(11):1865. https://doi.org/10.3390/vaccines10111865

Tanriover, Mine Durusu, Ozlem Altuntas Aydin, Rahmet Guner, Orhan Yildiz, Ilhami Celik, Hamdi Levent Doganay, Sukran Kose, Sila Akhan, Emin Halis Akalin, Zafer Sezer, and et al. 2022. "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial" Vaccines 10, no. 11: 1865. https://doi.org/10.3390/vaccines10111865

Tanriover, M. D., Aydin, O. A., Guner, R., Yildiz, O., Celik, I., Doganay, H. L., Kose, S., Akhan, S., Akalin, E. H., Sezer, Z., Ozdarendeli, A., Unal, S., & on behalf of the TURKOVAC Study Group. (2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines, 10(11), 1865. https://doi.org/10.3390/vaccines10111865